Epican

Epican is a biotechnology company specializing in epigenetic-based liquid biopsy for early cancer detection and monitoring. Founded on the pioneering research of Professor He Chuan from the University of Chicago, the company utilizes a proprietary 5-hydroxymethylcytosine (5hmC) sequencing platform to detect cancer-specific signatures in circulating cell-free DNA. This non-invasive approach allows for the highly sensitive detection of various solid tumors, including liver, lung, and gastrointestinal cancers, from a simple blood sample. Epican provides a range of diagnostic products and services aimed at early screening, minimal residual disease (MRD) monitoring, and personalized treatment guidance. Headquartered in Shanghai, the company is a key portfolio company of Viva BioInnovator and maintains strong academic and clinical collaborations to advance precision oncology.